Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure.

The effects of chronic treatment with growth hormone (porcine GH, 0.56 mg ⋅ kg-1 ⋅ day-1sc) were examined in dogs with heart failure induced by rapid ventricular pacing (240 beats/min) for 4 wk. Fourteen conscious dogs were studied 2-3 wk after surgical instrumentation with catheters in the descending aorta and left atrium, a pressure gauge in the left ventricle (LV), a flow probe around the ascending aorta, pacing leads on the ventricular free wall and left atrium, and ultrasonic crystals on the opposing anterior and posterior endomyocardium of the LV. GH treatment for 4 wk significantly increased both body weight and plasma insulin-like growth factor 1 (IGF-1) compared with vehicle-treated dogs ( P < 0.01, +2.0 ± 0.5 vs. +0.3 ± 1.1 kg; 1,043 ± 218 vs. 241 ± 64 ng/ml, respectively). However, the changes in resting LV systolic (i.e., both isovolumic and ejection phases) and diastolic function (i.e., isovolumic relaxation time constant τ) and the systemic vascular resistance were similar for the GH- and vehicle-treated groups during the development of heart failure. LV contractile reserve, assessed with step infusion of isoproterenol or dobutamine challenge, was markedly attenuated after heart failure, but there were no differences between the GH- and vehicle-treated groups. During the progression of heart failure, the increases in plasma atrial natriuretic peptide correlated ( P < 0.01) directly with left atrial pressure and inversely with LV circumferential fiber shortening. However, GH treatment did not substantially modify these relationships. In addition, renal function and myocardial ultrastructure at the advanced stage of heart failure also showed similar changes for the GH- and vehicle-treated groups. We conclude that in conscious dogs during the development of congestive heart failure produced by rapid ventricular pacing, GH at a dose that increases body weight and plasma IGF-1 levels does not affect LV performance or systemic vascular dynamics.

[1]  C. Peter,et al.  Pharmacological and Toxicological Effects of Chronic Porcine Growth Hormone Administration in Dogs , 1998, Toxicologic pathology.

[2]  W. Grossman,et al.  GH replacement fails to improve ventricular function in hypophysectomized rats with myocardial infarction. , 1996, The American journal of physiology.

[3]  J. Ross,et al.  Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. , 1996, Circulation.

[4]  B. Biondi,et al.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[5]  J. L. Swain,et al.  Growth hormone for heart failure--cause for cautious optimism. , 1996, The New England journal of medicine.

[6]  R. Clark,et al.  Growth hormone improves cardiac performance in experimental heart failure. , 1995, Circulation.

[7]  J. Ross,et al.  Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. , 1995, The Journal of clinical investigation.

[8]  S. Vatner,et al.  Effects of hypertrophy on left atrial and ventricular compliance and plasma ANF levels in conscious dogs. , 1995, American Journal of Physiology.

[9]  S. Vatner,et al.  Myocardial B-adrenergic receptor function during the development of pacing-induced heart failure , 1994 .

[10]  S. Yusuf,et al.  Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry , 1993 .

[11]  S. Vatner,et al.  Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. , 1993, The American journal of physiology.

[12]  S. Yusuf,et al.  Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. , 1993, Journal of the American College of Cardiology.

[13]  M. Redfield,et al.  Cardiorenal and Neurohumoral Function in a Canine Model of Early Left Ventricular Dysfunction , 1993, Circulation.

[14]  S. Vatner,et al.  Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. , 1993, The Journal of clinical investigation.

[15]  P. Molinoff,et al.  Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing. , 1991, Circulation research.

[16]  I. Mirsky,et al.  Effects of beta-adrenergic stimulation with dobutamine on isovolumic relaxation in the normal and failing human left ventricle. , 1991, Circulation.

[17]  S. Vatner,et al.  Alterations in myocardial contractility in conscious dogs with dilated cardiomyopathy. , 1991, The American journal of physiology.

[18]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[19]  Measurement of ventricular relaxation. An alternative index of isovolumic relaxation to the time constant. , 1989, Journal of pharmacological methods.

[20]  T. Ogihara,et al.  Plasma Atrial Natriuretic Peptide Level As an Index for the Severity of Congestive Heart Failure , 1987, Clinical cardiology.

[21]  N. Reichek,et al.  Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. , 1987, Circulation.

[22]  R. Rodeheffer,et al.  Atrial pressure and secretion of atrial natriuretic factor into the human central circulation. , 1986, Journal of the American College of Cardiology.

[23]  E. Bates,et al.  The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. , 1986, Circulation.